CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018

Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.

Pipeline
This is the actual pipeline sponsors use to get their applcaitions to FDA.

Drugs treating conditions related to the central nervous system (CNS) are so far among the most dominant in what looks to be a second consecutive busy year of reviews and approvals for the US FDA's Center for Drug Evaluation and Research (CDER).

Notably among the at least eight novel CNS drugs in CDER's 2018 preliminary pipeline are three anti-calcitonin gene-related peptide (anti-CGRP)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet